Table 1.
Summary of clinical trials targeting mTOR in HNSCC tumours.
| Inhibitor | Phase | Status | Targeted Pathway | Targeted Tumour | Reference |
|---|---|---|---|---|---|
| Palbociclib + Gedatolisib | I | Recruiting | CDK4/6 + mTOR | Advanced HNSCC | NCT03065062 |
| BYL719 | II | Recruiting | PI3K | Recurrent or Metastatic HNSCC | NCT02145312 |
| Everolimus + Palbociclib + Trametinib | I | Recruiting | mTOR + CDK4/6 + MEK | Malignant neoplasms of Oral cavity | NCT03065387 |
| CC-115 | I | Active, not recruiting | Dual DNA-PK and TOR kinase | Advanced HNSCC | NCT01353625 |
| PQR 309 | I | Active, not recruiting | PI3K/mTOR/AKT | Advanced HNSCC | NCT02483858 |
| Temsirolimus | II | Completed | mTOR | HNSCSC | NCT01172769 |
| Sirolimus | I/II | Completed | mTOR | Advanced HNSCC | NCT01195922 |
| Temsirolimus + Paclitaxel + Carboplatin | I/II | Completed | mTOR | Recurrent or Metastatic HNSCC | NCT01016769 |